Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

AIMS: Direct‐acting antiviral agents (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug–drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood. We assessed the clinical impact of possible pharmacokinetic (P...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Marra, Fiona, Höner zu Siederdissen, Christoph, Khoo, Saye, Back, David, Schlag, Michael, Ouwerkerk‐Mahadevan, Sivi, Bicer, Ceyhun, Lonjon‐Domanec, Isabelle, Jessner, Wolfgang, Beumont‐Mauviel, Maria, Kalmeijer, Ronald, Cornberg, Markus
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Drug Interactions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5903235/
https://ncbi.nlm.nih.gov/pubmed/29345798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13519
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky